HUE033306T2 - Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog - Google Patents

Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog Download PDF

Info

Publication number
HUE033306T2
HUE033306T2 HUE06712292A HUE06712292A HUE033306T2 HU E033306 T2 HUE033306 T2 HU E033306T2 HU E06712292 A HUE06712292 A HU E06712292A HU E06712292 A HUE06712292 A HU E06712292A HU E033306 T2 HUE033306 T2 HU E033306T2
Authority
HU
Hungary
Prior art keywords
cancer
drug
dose
day
patient
Prior art date
Application number
HUE06712292A
Other languages
English (en)
Hungarian (hu)
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033306(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of HUE033306T2 publication Critical patent/HUE033306T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE06712292A 2005-01-26 2006-01-25 Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog HUE033306T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06

Publications (1)

Publication Number Publication Date
HUE033306T2 true HUE033306T2 (hu) 2017-11-28

Family

ID=36740357

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE06712292A HUE033306T2 (hu) 2005-01-26 2006-01-25 Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog
HUS1700032C HUS1700032I1 (hu) 2005-01-26 2017-08-01 Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1700032C HUS1700032I1 (hu) 2005-01-26 2017-08-01 Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog

Country Status (21)

Country Link
EP (1) EP1849470B2 (en:Method)
JP (1) JP5576591B2 (en:Method)
KR (1) KR101468216B1 (en:Method)
AU (1) AU2006209547C1 (en:Method)
BE (1) BE2017C028I2 (en:Method)
CA (1) CA2594713A1 (en:Method)
CY (2) CY1119393T1 (en:Method)
DK (1) DK1849470T4 (en:Method)
ES (1) ES2630002T5 (en:Method)
FI (1) FI1849470T4 (en:Method)
FR (1) FR17C1028I2 (en:Method)
HU (2) HUE033306T2 (en:Method)
LT (2) LT1849470T (en:Method)
LU (1) LUC00036I2 (en:Method)
NL (1) NL300889I2 (en:Method)
PL (1) PL1849470T5 (en:Method)
PT (1) PT1849470T (en:Method)
RU (1) RU2394581C2 (en:Method)
SI (1) SI1849470T2 (en:Method)
TW (1) TWI362265B (en:Method)
WO (1) WO2006080327A1 (en:Method)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
ES2630002T5 (es) 2005-01-26 2024-09-19 Taiho Pharmaceutical Co Ltd Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) * 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
KR20120050975A (ko) 2009-07-22 2012-05-21 그뤼넨탈 게엠베하 산화-민감성 오피오이드를 위한 내변조성 용량형
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
HRP20171506T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
EP2746404B1 (en) 2011-08-16 2017-12-06 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EP2829611A4 (en) 2012-03-14 2015-12-02 Nisshin Pharma Inc SULFURAMINOUS-SUSTAINABLE COMPOSITION
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
KR101848131B1 (ko) 2013-03-27 2018-04-11 다이호야쿠힌고교 가부시키가이샤 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
HRP20201691T1 (hr) * 2013-03-27 2020-12-25 Taiho Pharmaceutical Co., Ltd. Antitumorni agens koji uključuje irinotekan hidroklorid hidrat
NZ714014A (en) * 2013-05-17 2017-06-30 Taiho Pharmaceutical Co Ltd Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
BR112015029616A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem resistente à adulteração com perfil de liberação bimodal
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
PL3042669T3 (pl) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
CN107889459A (zh) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
UA125119C2 (uk) * 2016-01-08 2022-01-12 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний засіб, що містить імуномодулятор і підсилювач протипухлинного ефекту
JP6882205B2 (ja) 2016-02-05 2021-06-02 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
PT884051E (pt) * 1996-09-24 2005-03-31 Taiho Pharmaceutical Co Ltd Inibidores de metasteses cancerosas contendo derivados de uracilo
ES2630002T5 (es) 2005-01-26 2024-09-19 Taiho Pharmaceutical Co Ltd Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa

Also Published As

Publication number Publication date
RU2394581C2 (ru) 2010-07-20
AU2006209547A1 (en) 2006-08-03
HUS1700032I1 (hu) 2017-09-28
CY2017029I2 (el) 2018-02-14
FR17C1028I1 (en:Method) 2017-09-29
ES2630002T5 (es) 2024-09-19
NL300889I1 (nl) 2017-08-14
FI1849470T4 (fi) 2024-03-22
CY1119393T1 (el) 2018-02-14
BE2017C028I2 (en:Method) 2025-09-10
CY2017029I1 (el) 2018-02-14
SI1849470T1 (sl) 2017-10-30
LUC00036I1 (en:Method) 2017-10-02
EP1849470A4 (en) 2010-12-08
LTPA2017024I1 (lt) 2017-08-10
EP1849470A1 (en) 2007-10-31
PT1849470T (pt) 2017-09-22
KR20070104559A (ko) 2007-10-26
AU2006209547B2 (en) 2011-05-26
KR101468216B1 (ko) 2014-12-03
RU2007132181A (ru) 2009-03-10
AU2006209547C1 (en) 2022-04-07
DK1849470T3 (en) 2017-08-14
FR17C1028I2 (fr) 2018-11-02
NL300889I2 (nl) 2018-01-16
SI1849470T2 (sl) 2024-05-31
LT1849470T (lt) 2017-07-25
CA2594713A1 (en) 2006-08-03
PL1849470T5 (pl) 2024-06-10
JP5576591B2 (ja) 2014-08-20
PL1849470T3 (pl) 2017-11-30
TW200637562A (en) 2006-11-01
EP1849470B2 (en) 2024-03-20
EP1849470B1 (en) 2017-06-21
JPWO2006080327A1 (ja) 2008-06-19
DK1849470T4 (en) 2024-04-02
TWI362265B (en) 2012-04-21
LUC00036I2 (en:Method) 2017-12-01
LTC1849470I2 (lt) 2019-10-25
ES2630002T3 (es) 2017-08-17
WO2006080327A1 (ja) 2006-08-03

Similar Documents

Publication Publication Date Title
HUE033306T2 (hu) Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US20070232592A1 (en) Therapeutic Compositions Containing at Least one Pyrrolobenzodiazepine Derivative and Fludarabine
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
WO1992021345A1 (en) Composition, method and kit for potentiating antitumor activity and for curing tumor
JP2000273044A (ja) 副作用軽減剤
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
CN107137417B (zh) 一种用于治疗恶病质的药物组合物及其应用
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
TWI615145B (zh) 含伊立替康鹽酸鹽水合物之抗腫瘤劑
JP6895688B2 (ja) 血液がんの新規治療法及び新規治療剤
ES2896051T3 (es) Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral
WO2018121669A1 (zh) 一种用于治疗癌症的药物组合物及其应用
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
TW202140018A (zh) 含有尿嘧啶衍生物化合物之抗腫瘤效果增強劑
TW202203942A (zh) 血液癌之新穎治療法及新穎治療劑
CN115581703A (zh) 复方吉西他滨组合物及应用
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法
TW201143769A (en) Anti-tumor agent combined with kinase inhibitor